JMDC Inc.
FY2026 Q3 Financial Results Presentation
Consolidated revenue amounted to JPY 36,488 million (YoY +23%), operating income was JPY 7,767 million (YoY +37%), and net income attributable to owners of parent was JPY 4,811 million (YoY +28%), showing steady growth.
Key Figures
- Consolidated Revenue: JPY 36,488 million (YoY +23%)
- Consolidated EBITDA: JPY 9,682 million (YoY +27%)
- Net Income Attributable to Owners of Parent: JPY 4,811 million (YoY +28%)
AI要約
Performance Overview
In the cumulative Q3 of FY2026, consolidated revenue reached JPY 36,488 million (YoY +23%) and consolidated EBITDA was JPY 9,682 million (YoY +27%), maintaining solid growth. The core Health Big Data segment drove performance, with revenue up 26% QoQ and EBITDA up 32%. The Pharmaceutical Sales & Marketing transaction amount increased 43% YoY, contributing to overall revenue expansion. Operating income was JPY 7,767 million (YoY +37%) and net income attributable to owners of parent was JPY 4,811 million (YoY +28%).
Management Viewpoints and Outlook
Growth in the Health Big Data segment continued through Q3, with all businesses demonstrating balanced growth. The utilization of generative AI to create new insights and strategic partnerships with electronic medical record providers are positioned as growth drivers. Progress toward full-year earnings guidance remains on track, and efforts to achieve the target will continue. Plans include strengthening valuable partnerships in response to post-pandemic shifts in market needs.
